On October 24, Bayer announced an exclusive licensing agreement with Dewpoint Therapeutics for a cardiology project aimed at treating patients with dilated cardiomyopathy (DCM) carrying specific mutations. This marks the first option exercised under the research collaboration between Bayer and Dewpoint Therapeutics that began in November 2019, leveragingDewpointProprietary platform of biomolecular condensates and Bayer's small molecule R&D capabilities to develop new therapies for cardiovascular and kidney diseases.DewpointWill receive upfront and additional development and commercial milestone payments, estimated at $424 million, excluding royalties.This collaboration is through Bayer's strategic investment armLeaps by BayerParticipateDDewpoint inAfter the Series A financing in January 2019.Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer's pharmaceuticals division, stated:"One of the biggest challenges in drug discovery lies in addressing the undruggable human proteome. The emerging paradigm of biomolecular condensates expands the traditional druggable target space of small molecules by uncovering new targets and novel approaches to previously difficult-to-drug targets. We are excited to collaborate withDewpoint"Together, we are participating in this new wave of innovation, as our goal is to provide transformative drugs for cardiovascular patients with the greatest unmet needs."
Dilated cardiomyopathy (DCM) is a myocardial disease characterized by enlarged ventricles that struggle to pump blood effectively. This licensing program focuses on an innovative approach to address a specific form of DCM associated with mutations that lead to the formation of disease-related condensates. This form of dilated cardiomyopathy is a severe condition with significant unmet medical needs, marked by early-onset heart failure and frequent life-threatening arrhythmias.
Dewpoint Therapeutics CEO Ameet Nathwani said:"We are excited about the new discoveries achieved through our collaboration with Bayer, which have tremendous potential to transform the treatment of DCM. The licensing of the first discovery project highlights our proprietaryCoacervateThe scientific validation of the method, which identifies and targets the underlying causes of complex diseasesCoacervateDriving Factors. The preclinical study results of this project indicate that,Coacervate"The modified small molecules can reverse the fundamental disease process. We are pleased that Bayer has exercised the licensing rights to this exciting project, which will further strengthen our ongoing collaboration to explore innovative treatments for cardiovascular and renal diseases."Follow the official account below to see the world!
